Lemaitre Vascular Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lemaitre Vascular Inc 's ROA in the second quarter of 2026?
Lemaitre Vascular Inc achieved a return on average assets (ROA) of 10.96 % in its second quarter of 2026, this is above LMAT's average return on assets of 9.49%.
Lemaitre Vascular Inc assets over the 12 months ending in its second quarter of 2026 are valued at $617 million

ROA has improved compared to 10.44% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 91 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 584, from total ROA ranking in the first quarter of 2026 at 720.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	14.06 %	16.46 %	14.71 %	61.68 %	61.54 %
Y / Y Net Income Change	38.27 %	42.39 %	39.32 %	55.84 %	16.51 %
Net Income (TTM) in million	68	62	58	53	47
Return On Assets (TTM)	10.96 %	10.44 %	10.03 %	9.6 %	9.42 %
LMAT's Total Ranking	# 584	# 720	# 659	# 683	# 637
Total Assets (TTM) in million	641	630	616	584	562
Seq. Total Assets Change	1.75 %	2.25 %	5.4 %	4.02 %	3.89 %
Seq. Net Income Change	21.51 %	0.62 %	-10.25 %	26 %	25.14 %

LMAT's 5 Years Annual ROA >> Back to LMAT Management Effectiveness >> Compare LMAT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 24
Sector	# 92
Overall	# 560

Return On Assets Statistics
High	Average	Low
17.06 %	9.49 %	3.19 %
(Jun 30 2018)

Financial Statements
Lemaitre Vascular Inc 's Assets	$ 641 million	LMAT's Balance sheet
Lemaitre Vascular Inc 's Income	$ 19 million	Quarterly LMAT's Income Statement
LMAT's Income by Division		See LMAT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	14.71 %	62.65 %	11.07 %	6.64 %	17.48 %
Total Assets in million	616	537	330	297	279
Y / Y Net Income Change	31.1 %	46.28 %	45.89 %	-23.31 %	26.8 %
Net Income in million	58	44	30	21	27
Annual Return On Assets	9.38 %	8.2 %	9.12 %	6.95 %	9.66 %

LMAT's 5 Years Annual ROA >> Back to LMAT Management Effectiveness >> Compare LMAT ROA to its Competitors

Comment on LMAT's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 9.38 % compared to prior year, due to annual net income growth of 31.1 % to $57.73 million, while value of Lemaitre Vascular Inc 's overall assets grew just by 14.71 % to $615.69 million, compared to $615.69 a year before.

More Return On Assets Ratios
LMAT's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LMAT's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LMAT's Competitors
Subscribers only: Roa for Lemaitre Vascular Inc 's Suppliers
Subscribers only: Return On Assets for LMAT's Customers

You may also want to know
LMAT's Roi	LMAT's Inventory Turnover Ratio	LMAT's Growth Rates	LMAT's Dividend Comparisons
	LMAT's Profitability Ratios	LMAT's Asset Turnover Ratio	LMAT's Dividend Growth
LMAT's Roe	LMAT's Valuation Ratios	LMAT's Financial Strength Ratios	LMAT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Meiragtx Holdings Plc	29.37 %
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %
Acadia Pharmaceuticals Inc	24.38 %
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %

Date modified: 2026-09-11T09:47:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.